Effect of D-003, a mixture of high molecular weight primary acids from sugar cane wax, on CL4C-induced liver acute injury in rats

Drugs under Experimental and Clinical Research

Volumn 28, Issue 5, 2002, Pages 177-183

  Noa, M ^a   Mendoza, S ^a   Mas, R ^a   Mendoza, N ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ALIPHATIC CARBOXYLIC ACID; ANTITHROMBOCYTIC AGENT; CARBON TETRACHLORIDE; D 003; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN; OCTACOSANOIC ACID; OLIVE OIL; UNCLASSIFIED DRUG; WAX;

ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CELL INCLUSION; CELL SWELLING; CONTROLLED STUDY; DOSE RESPONSE; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; INFLAMMATORY INFILTRATE; LIPID PEROXIDATION; LIVER CELL; LIVER INJURY; LIVER NECROSIS; LIVER PROTECTION; LIVER TOXICITY; MALE; NONHUMAN; RAT; SUGARCANE;

ANIMALS; ANTIOXIDANTS; CARBON TETRACHLORIDE; FATTY ACIDS; HEPATOCYTES; LIPID PEROXIDATION; LIVER; LIVER DISEASES; MALE; PHYTOTHERAPY; RATS; RATS, SPRAGUE-DAWLEY; SACCHARUM;

EID: 0037005461     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Anderson K.M., Wilson P.W.F., Odell P.M., et al. An updated coronary risk profile: A statement for health professionals. Circulation, 83, 356, 1991.
2. Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results I. Reduction in the incidence of coronary heart disease. JAMA, 251, 351, 1984.
3. Lipid Research Clinics Program The lipid research clinics coronary primary prevention trial results II. The relationship of reduction in the incidence of coronary heart disease to cholesterol lowering. JAMA, 251, 365, 1984.
4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet, 344, 1383, 1994.
5. Sacks F.M., Pfeffer M.A., Moy L.A., et al. for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N. Engl. J. Med., 335, 1001, 1996.
6. Tonkin A., Aylward P., Colqhoun D., et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N. Engl. J. Med., 339, 1349, 1998.
7. Shepherd S., Cobbe S.M., Ford I., et al. for the West of Scotland Coronary Prevention. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333, 1301, 1995.
8. Downs J.R., Clearfield M., Weiss S., et al. for the AFCAPS/TexCAPS Rsearch Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA, 279, 1615, 1998.
9. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol. Ther., 79, 205, 1998.
10. Farnier M., Davignon J. Current and future treatment of hyperlipidemia: The role of statins. Am. J. Cardiol., 82, 3, 1998.
11. Farmer J.A., Gotto A.M. Choosing the right lipid-regulating agent: A guide to selection. Drugs, 52, 649, 1996.
12. Board of American Society of Health-System Pharmacists (ASHP). Antilipemic agents. in: American Society of Health-System Pharmacists Inc. (Eds.). "American Formulary Hospital Service (AFHS) Drug Information, 2000." ASHP, Bethesda, 2000, pp 1620-1657.
13. Plaa G.L., Hewitt W.R. Detection and evaluation of chemically induced liver injury. In: Wallace Hayes A. (Ed.). "Principles and Methods of Toxicology." Second Edition, Raven Press Ltd., New York, 1989, pp. 599-628.
14. Recknagel R.O., Glende E.A., Waller R.L., Lowry K. Lipid peroxidation: Biochemistry, measurement, and significance in liver cell injury. In: Plaa G., Hewitt, W.R. (Eds.). "Toxicology of the Liver." Raven Press, New York, 1982, pp. 213-241.
15. Wendel A. Measurement of in vivo lipid peroxidation and toxicological significance. Free Radic. Biol. Med., 3, 355, 1987.
16. González L., Marrero D., Laguna A., et al. inventors; Laboratorios Dalmer SA, assignee: Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa patent 98-2744. December 30, 1998.
17. Gámez R., Mendoza S., Más R., et al. Dose-dependent cholesterol lowering effects of D-003 on normocholesterolemic rabbits. Curr. Ther. Res., 61, 8, 2000.
18. Mendoza S., Gámez R., Noa M., Más R., Castaño G. The effects of D-003 and policosanol on the lipid profile and endothelial cells in normocholesterolemic rabbits: A head to head comparison. Curr. Ther. Res., 62, 209, 2001.
19. Molina V, Arruzazabala M.L., Carbajal D., Más R., Valdés S. Antiplatelet and antithrombotic effects of D003. Pharmacol. Res., 42, 137, 2000.
20. Molina V., Arruzazabala M.L., Carbajal D., Más R. D-003, a new compound with effects on arachidonic acid metabolites. Prostagl. Leuk. Essent. Fatty Acids, 2002 (in press).
21. Menéndez R., Mas R., Amor A.M., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D003, a mixture of very long chain saturated fatty acids. Pharmacol. Res., 44, 299-304, 2001.
22. Mas R. Policosanol. Drugs of the Future, 25, 569, 2000.
23. Más R., Castaño G., Illnait J., et al. Effect of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin. Pharmacol. Ther., 65, 439, 1998.
24. Castaño G., Más R., Arruzazabala M.L., et al. Effects of policosanol, pravastatin on lipid profile, platelet aggregation, endothelemia in older hypercholesterolemic patients. Int. J. Clin. Pharmacol. Res., XIX, 105, 1999.
25. Fernández J.C., Más R., Castaño G., et al. Comparison of the efficacy, safety and tolerability of policosanol versus fluvastatin in elderly hypercholesterolemic women. Clin. Invest., 21, 103, 2001.
26. Mirkin A., Mas R., Martinto M., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int. J. Clin. Pharmacol Res., XXI, 31, 2001.
27. Crespo N., Illnait J., Más R., et al. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia an non insulin dependent diabetes mellitus. Int. J. Clin. Pharmacol. Res., XIX, 117, 1999.
28. Menéndez R., Mas R., Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003. Can. J. Physiol. Pharmacol., 80, 13, 2002.
29. Menéndez R., Fraga V., Amor A.M., González R.M., Más R. Oral administration of policosanol inhibits in vitro cooper ion-induced rat lipoprotein peroxidation. Physiol. Behav., 67, 1, 1999.
30. Menéndez R., Más R., Amor A.M., et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br. J. Clin. Pharm., 50, 225, 2000.
31. Menéndez R, Más R., Amor A., et al. Effects of policosanol on the low density lipoprotein (LDL) isolated on hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation. A randomised, double-blinded pilot study. Curr. Ther. Res., 61, 609, 2000.
32. Gámez R., Más R., Noa M., et al Acute and subchronic oral toxicity of D-003 in rats. Toxicol. Lett., 118, 31, 2000.
33. Gámez R., González J.E., Rodeiro I., et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J. Med. Food., 4, 85, 2001.
34. Gámez R., Rodeiro I., Fernández I., Acosta P.C. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: A mixture of very long chain fatty acids. Teratog. Carcinogen Mutag., 2001 (in press).
35. Rodríguez M.D., Gámez R., González J.E., García H., Acosta C.P., Goicochea E. Lack of developmental toxicity of D-003: a mixture of long-chain fatty acids in rats. Fd Chem. Toxicol., 41, 89, 2003.
36. Coro R.M., Borrajero I. DIGIPAT. Un sistema cubano para morfometría de imágenes. Rev. Latinoam. Patol., 39, 9, 1996.
37. Charbonneau M., Iijima M., Coté M.G., Plaá G.L. Temporal analysis of rat liver injury following potentiation of carbon tetrachloride hepatotoxicity with ketonic or ketogenic compounds. Toxicology, 32, 95, 1985.
38. Martínez-Calva A., Campos-Apáez E., Rosales-Vega E., Mourelle M. Vitamin E improves membrane lipid alterations induced by CCL4 intoxication. J. Appl. Toxicol., 4, 270, 1984.
39. Muriel P., Mourelle M. Prevention by silymarin of membrane alterations in acute CCL4 liver damage. J. Appl. Toxicol., 10, 275, 1990.
40. Merino N., González R., González A., Remirez D. Histopathological evaluatin on the effect of red propolis on liver damage induced by CCL4 in rats Arch Med. Res., 27, 285, 1996.
41. Nagai H., Aoki M., Shimazawa T., et al. Effect of Oky-046 and ONO-3708 on liver injury in mice. Jpn. J. Pharmacol., 51, 191, 1989.